Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vericel Corporation (NQ: VCEL )

51.55 -0.67 (-1.28%)
Streaming Delayed Price Updated: 3:21 PM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 329,554
Open 51.62
Bid (Size) 51.55 (2)
Ask (Size) 51.70 (2)
Prev. Close 52.22
Today's Range 50.87 - 53.14
52wk Range 30.18 - 53.05
Shares Outstanding 46,631,158
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A Glimpse Into The Expert Outlook On Vericel Through 4 Analysts
Via Benzinga
Trading SMID Biotech Stocks In A Volatile Market
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets

Performance

YTD
+47.79%
+47.79%
1 Month
+23.59%
+23.59%
3 Month
+8.48%
+8.48%
6 Month
+31.51%
+31.51%
1 Year
+32.93%
+32.93%

More News

Read More
The 3 Highest-Rated Medical Stocks You Can Buy Today
Via InvestorPlace
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
From Vericel Corporation
Via GlobeNewswire
Critical Insights From Vericel Analyst Ratings: What You Need To Know
Via Benzinga
Analyst Scoreboard: 5 Ratings For Vericel
Via Benzinga
VCEL Stock Earnings: Vericel Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
From Vericel Corporation
Via GlobeNewswire
It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility
Via Talk Markets
A Closer Look at 4 Analyst Recommendations For Vericel
Via Benzinga
Earnings Scheduled For February 29, 2024
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Vericel: Here's What You Need To Know
Via Benzinga
Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
From Vericel Corporation
Via GlobeNewswire
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
Via InvestorPlace
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
From Vericel Corporation
Via GlobeNewswire
5 medical stocks growing earnings by triple digits
Via MarketBeat
Topics Economy
Exposures Economy
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
From Vericel Corporation
Via GlobeNewswire
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
From Vericel Corporation
Via GlobeNewswire
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
From Vericel Corporation
Via GlobeNewswire
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
Via Benzinga
3 Biotech Stocks That Could Boom or Bust by 2025
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.